ArticleScientific reports2025
Synergistic potential of clindamycin hydrochloride loaded on zinc oxide nanoparticles: A novel approach to combat multidrug-resistant infections.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of antimicrobial resistance (AMR) presents a critical challenge to global health, necessitating novel strategies to enhance the efficacy of existing antibiotics. This study investigated the potential of combining zinc oxide nanoparticles (ZnO NPs) with clindamycin to overcome bacterial resistance and improve treatment outcomes. Thus, the loading of clindamycin into ZnO nanoparticles was achieved using varying drug-to-nanocarrier ratios (1:20, 1:10, 1:5), and the formulations were characterized for loading efficiency, particle size, and zeta potential. As well as the antimicrobial assessment of zinc oxide nanoparticles, clindamycin drug and the drug loaded onto ZnO NPs was evaluated against resistant Gram-positive, Gram negative bacterial and one fungal species (Candida albicans). The results revealed a significant increase in drug loading efficiency with optimized nanoparticle formulations. Furthermore, in vitro release studies showed that ZnO NPs provided sustained drug release, offering a controlled and prolonged therapeutic effect. It was concluded that the combination of ZnO NPs and clindamycin demonstrates significant promise for addressing the challenges posed by AMR, indicated by lower the values of both MIC and MBC as well increasing the inhibition zone diameter, providing an innovative and efficient solution for the treatment of several infections, particularly those exhibiting drug resistance profile. The cytotoxicity of ZnO nanoparticles (ZnO NPs), clindamycin, and their nanocomposite was tested in human gingival fibroblasts. The CC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.